Agreement - January 27, 2016
Curida signs agreement with Serviceproduksjon
Norwegian CDMO Curida has signed a framework-agreement with Serviceproduksjon, a subsidary to the Norwegian Pharmace Association. The agreement entails validation of a chemical analytical method for use in analysis of tablets and routine analysis of the particular drug. “Serviceproduksjon received offers from three other contract laboratories and chose Curida based on competency, competitive pricing and […]
Uncategorized - January 21, 2016
14 new OCC members in 2015
Oslo Cancer Cluster had a tremendous growth in the number of members in 2015: 14 new ones joined the cluster. In total the cluster now comprise of 75 members. Among the new companies are Medivir, Phoenix Solutions, Regenics, Steenstrup Stordrange, Myhere, SAS Institute, Celgene, HealthCap, Astellas Pharma, Curida, Crown Bioscience, Questback, Larix, Oslo Life Science Advisors Source: Oslo Cancer Cluster
Uncategorized - December 29, 2015
Thermo Fisher moves into OCC
Thermo Fisher Scientific will rent over 800m2 in the Oslo Cancer Cluster Incubator. Thermo Fisher Scientific is expanding and during the first quarter of 2016 the entire management team, production team and parts of the R&D milieu will move to the Oslo Cancer Cluster Incubator. The company plans to create a creative Google-like environment with a particular […]
Uncategorized - September 3, 2015
The grand opening of Oslo Innovation Park
The grand opening of the Oslo Cancer Cluster Innovation Park took place on the 24th of August. The opening ceremony involved over 290 invited guests who celebrated the initiators Jónas Einarsson and Kaare Norum for turning the radical idea of an oncology innovation park integrating a high school into reality. In his speech, Jónas Einarsson told the […]
Funding - July 3, 2015
Norway Invests in Biomedical Research
The Norwegian Research Council recently announced four large investments in biomedical research for a total of 255 MNOK. Out of the total, 60 MNOK will go to to sequencing and precision medicine, 80 MNOK to national biobanks, 65 MNOK to brain research and 50 MNOK to Norwegian Clinical Research Infrastructure Network. “This is great news. […]
Funding - December 3, 2014
Oslo Cancer Cluster Names Research Grant Winners
Oslo Cancer Cluster recently named three winners in a competition seeking collaborative projects involving immuno-oncology. The three, BerGen Bio, Targovax and Ultimovacs each will receive MNOK 0,4 from Innovation Norway. BerGenBio will use the award to prove that Axl kinase inhibition may provoke an anti-tumor immune response, working with partners from the University of Bergen, Oslo, […]
